预约演示

Merz makes a $185m bid for assets from bankrupt Acorda

2024-04-02

交易

上市批准并购引进/卖出

The deal includes Inbrija (levodopa inhalation powder) and Fampyra (fampridine), the latter marketed as Ampyra (dalfampridine) in the US. Image credit: Shutterstock/Andrii Sedykh.

Merz Therapeutics Inbrijaered an agreement to buy three comFampyra afampridine Acorda Therapeutics for $Ampyraa dalfampridine latter biotech filed for bankruptcy.

Merz Therapeuticsz is acting as a “stalking horse” bidder, meaning the assets cAcorda Therapeuticsre than the $185m opening bid if another company decides to swoop in at a higher price. These types of bids come into play in cases involving bankrupt companies.

The sale proceMerzs expected to end in June 2024, according to a 2 April press release by Merz.

The deal is for all US-based Acorda’s assets, including Inbrija (levodopa inhalation powder), and Ampyra (dalfampridine), the latter marketed as Fampyra (fampridine) outside of the US. Inbrija is used to treat patients with Parkinson’s disease whilst Ampyra/Fampyra is approved to help the improve walking ability in patients with multiple sclerosis.

Inbrija and Fampyra generatedAcordal sales of $31m and $Inbrijapectively in 2023. According to GloAmpyraa’dalfampridinelligence Centre, Fampyra uFampyrasefampridine over $500m in 2017. Inbrijae it lost exclusivity in 2018, gParkinson’s disease market.Ampyra Fampyra multiple sclerosis

Inbrija Inbrijao:Fampyra Pharma Intelligence Centre Fampyra

BioGaia gets grant for therapeutic microvesicles from probiotic bacteria

BioGaiaAnimal Health gets grant for reducing ammonia and carbon dioxide emissions from bovines

GlobalData is the parent company of Pharmaceutical Technology.

Elanco Animal Healthrda was a big player in the neurodegenerative disorder space, splashing $363m to acquire Finnish biopharma Biotie Therapies, a developer of Parkinson’s disease therapies, in 2016.

Acorda has since struggled financially as sales of its drugs weakened. Biogen, which had a 2009 license agreement for Fampyra outside the US, returned the rights to Acorda earlier this year. Shares in the company continued to dive and Acorda ultimately filed for bankruptcy, announced via a 1 April press release.

Merz will add Acorda’s medicines to Pharmaceutical Technology Xeomin (incobotulinumtoxinA). As per its US Food and Drug Administration (FDA) label, the botulinum compound is approved to treat chronic sialorrhea – otherwise known as excessive drooling, upper limb spasticity, and cervical dystonia, amongst others.

Merz Group’s COO Acordaergler said: “This investneurodegenerative disorderly to Merz Therapeutics’ growth strategy and expand our portfolio in the field of moveParkinson’s diseaseneurodegeneration.”

Acordating on the company’s bankruptcy filing, Acorda’s CEO Ron Cohen sBiogenAcorda’s management team and board have eFampyrad all of our strategic options, and follAcordaan exhaustive process believe that this option is in the best inAcorda of stakeholders.”